Experimental design:Radioligand binding to membrane-associated IGF1 receptors was performed in duplicate in 96- well OptiPlates. Membrane protein was incubated for 150 minutes at 25°C with 50 pM [125I- Tyr31]-human IGF1 in a total volume of 150 μl assay buffer (50 mM HEPES, 150 mM NaCl, 5 mM MgSO4, 0.01% Triton X-100, 0.1% HSA, Complete EDTA-free protease inhibitors), 50µg of WGA-coated PVT microspheres and increasing concentrations of human IGF1, human insulin or insulin 287 (typically between 0.1 and 10,000 nM). The assay was terminated by centrifugation of the plate at 2,000 RPM for 2 minutes and bound radioactivity quantified by counting in a Perkin Elmer TopCount NXT.Results:Binding of 125I-IGF1 to membrane-associated recombinant human IGF1 receptors was displaced with human IGF1, human insulin and insulin 287. Concentrations giving half-maximal inhibition of binding (IC50) were estimated to 0.27 nM (range 0.10-0.75 nM) for IGF1 and 167 nM (range 139-211) for HI. However, even at the highest concentration of insulin 287 (10,000 nM), 125I-IGF1 was hardly displaced. Thus, insulin 287 appears to have a very low affinity for human IGF1 receptors relative to human insulin in experiments performed in the presence of 0.1% human serum albumin.Furthermore, similar results were obtained using membrane-associated recombinant IGF1 receptors of rat and dog origin. Thus, insulin 287 appears to have a very low affinity for rat and dog IGF1 receptors.Conclusion:Insulin 287 appears to have a very low affinity for human, rat and canine IGF1 receptors relative to human insulin in experiments performed in the presence of 0.1% human serum albumin and a relative potency compared to HI could not be determined.
Experimental design:<br>Radioligand binding to membrane-associated IGF1 receptors was performed in duplicate in 96- well OptiPlates. Membrane protein was incubated for 150 minutes at 25°C with 50 pM [125I- Tyr31]-human IGF1 in a total volume of 150 μl assay buffer (50 mM HEPES, 150 mM NaCl, 5 mM MgSO4, 0.01% Triton X-100, 0.1% HSA, Complete EDTA-free protease inhibitors), 50<br>µg of WGA-coated PVT microspheres and increasing concentrations of human IGF1, human insulin or insulin 287 (typically between 0.1 and 10,000 nM). The assay was terminated by centrifugation of the plate at 2,000 RPM for 2 minutes and bound radioactivity quantified by counting in a Perkin Elmer TopCount NXT.<br>Results:<br>Binding of 125I-IGF1 to membrane-associated recombinant human IGF1 receptors was displaced with human IGF1, human insulin and insulin 287. Concentrations giving half-maximal inhibition of binding (IC50) were estimated to 0.27 nM (range 0.10-0.75 nM) for IGF1 and 167 nM (range 139-211) for HI. However, even at the highest concentration of insulin 287 (10,000 nM), 125I-IGF1 was hardly displaced. Thus, insulin 287 appears to have a very low affinity for human IGF1 receptors relative to human insulin in experiments performed in the presence of 0.1% human serum albumin.<br>Furthermore, similar results were obtained using membrane-associated recombinant IGF1 receptors of rat and dog origin. Thus, insulin 287 appears to have a very low affinity for rat and dog IGF1 receptors.<br>Conclusion:<br>Insulin 287 appears to have a very low affinity for human, rat and canine IGF1 receptors relative to human insulin in experiments performed in the presence of 0.1% human serum albumin and a relative potency compared to HI could not be determined.
正在翻译中..